STOCK TITAN

Vir Biotechnology, Inc. - VIR STOCK NEWS

Welcome to our dedicated page for Vir Biotechnology news (Ticker: VIR), a resource for investors and traders seeking the latest updates and insights on Vir Biotechnology stock.

Vir Biotechnology, Inc. (VIR) pioneers immunology solutions targeting complex infectious diseases through innovative platforms including antibody therapies, T cell engineering, and siRNA technology. This dedicated news hub provides investors and industry stakeholders with timely updates on clinical developments, strategic partnerships, and regulatory milestones.

Access authoritative updates on VIR's research pipeline, financial performance announcements, and scientific breakthroughs in infectious disease management. Our curated collection ensures transparent access to press releases spanning clinical trial progress, collaborative initiatives, and patent filings.

Key updates include advancements in hepatitis B/HIV therapies, influenza A research, and platform technology licensing agreements. Bookmark this page to efficiently monitor VIR's contributions to biotechnology and its evolving position in global health innovation.

Rhea-AI Summary
Vir Biotechnology announces acceptance of abstracts for presentation at AASLD The Liver Meeting
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.23%
Tags
none
-
Rhea-AI Summary
Vir Biotechnology to provide corporate update and report Q3 financial results on November 2, 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.34%
Tags
-
Rhea-AI Summary
Vir Biotechnology receives $50 million investment from BARDA to advance development of novel monoclonal antibody candidates and delivery solutions for COVID-19 and pandemic preparedness.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.11%
Tags
none
Rhea-AI Summary
Vir Biotechnology initiates Phase 1 trial for VIR-1388, an investigational T cell vaccine for HIV prevention
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.87%
Tags
-
Rhea-AI Summary
Vir Biotechnology, Inc. (Nasdaq: VIR) announced participation in investor conferences in September. Marianne De Backer, CEO, will participate in a fireside chat on September 12. Vir management will also host 1-on-1 investor meetings on September 13.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.07%
Tags
conferences
-
Rhea-AI Summary
Brii Biosciences reports positive interim results and updates on its therapies for HBV and PPD
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.57%
Tags
none
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.51%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.06%
Tags
-
Rhea-AI Summary
Vir Biotechnology's Phase 2 PENINSULA trial evaluating VIR-2482 for the prevention of symptomatic influenza A illness did not meet primary or secondary efficacy endpoints. The highest dose showed a non-statistically significant reduction of approximately 16% in influenza A protocol-defined illness and approximately 57% reduction in symptomatic influenza A illness according to CDC criteria. VIR-2482 was well tolerated with no safety signals identified. Further analysis is needed to understand the outcomes.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-44.9%
Tags
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.36%
Tags
management
Vir Biotechnology, Inc.

Nasdaq:VIR

VIR Rankings

VIR Stock Data

759.35M
101.72M
12.01%
76.71%
5.66%
Biotechnology
Biological Products, (no Disgnostic Substances)
Link
United States
SAN FRANCISCO